Crossject announces initiation of coverage by ODDO BHF
2023年11月28日 - 3:30PM
Rated “Outperform” with price target of €7.10
Analysts cite $60 million BARDA contract for
Crossject’s ZEPIZURE® as validation of platform
Dijon, France November 28, 2023, 07:30 CET -- Crossject
(ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company
developing needle-free auto-injectors for emergency
situations, announces initiation of coverage of its stock
by analysts at independent financial group ODDO BHF.
The ODDO BHF analysts rated Crossject as
“Outperform” with a price target of €7.10, citing the significant
advantages associated with the company’s needle-free ZENEO® device,
which enables easily administered injections to be delivered by
patients and untrained caregivers in a fraction of a second in
emergency situations. Crossject’s contract with the U.S. Biomedical
Advanced Research and Development Authority (BARDA) to procure
ZEPIZURE®, previously known as ZENEO® Midazolam, for nerve
agent-induced epileptic seizures, is an important validation of the
platform, the analysts said.
“The group’s expertise and the difference
vis-à-vis its rivals lies in its needle-free ZENEO device. The
injectable drug market represents more than 20% of the
pharmaceutical market, driven in part by auto-injection. We see
this innovation as offering a real improvement in patient comfort
and the assurance of an effective injection, particularly in
emergency situations,” ODDO BHF analysts Martial
Descoutures and Oussema Denguir said. “With a firm [BARDA]
order for $60m for its first candidate product ZENEO Midazolam, we
expect the first sales from 2024 pending approval at end-2023/start
of 2024. We also factor in the group’s two priority candidates
which will be launched on the market between 2024 and 2026 and see
the rest of the clinical portfolio as free option.”
The new initiation complements Crossject’s ongoing coverage by
the analysts from Invest Securities and Alpha Value.
All reports on Crossject prepared by analysts
represent the views of those analysts, and are not necessarily
those of Crossject. Crossject is not responsible for the content,
accuracy or timelines provided by the analysts.
A copy of the research report may be obtained directly from the
analysts at ODDO BHF by contacting Martial Descoutures at
martial.descoutures@oddo-bhf.com.
ODDO BHF SCA and the issuer have agreed that ODDO BHF SCA will
produce and disseminate investment recommendations on the issuer
equity side as a service to the issuer.This Research Report does
not constitute a personal recommendation or take into account the
particular investment objectives, financial situations, or needs of
individual clients. Clients should consider whether any advice or
recommendation in this research is suitable for their particular
circumstances and, if appropriate, seek professional advice,
including tax advice.This Research Report is for the use of
eligible counterparties and professional clients of ODDO BHF SCA
only.
About ODDO BHF
ODDO BHF is a Franco-German financial group with a history
dating back more than 170 years. It was founded by a French
family-owned bank and a German bank specializing in small and
mid-sized companies. With 2,700 employees, of which 1,400 in
Germany and Switzerland and 1,300 in France and Tunisia, and more
than €128 billion in client assets under management, ODDO BHF
operates in three main business lines – private banking, asset
management, and corporate and investment banking.
About Crossject
Crossject SA (Euronext: ALCJ;
www.crossject.com) is an emerging specialty pharma company. It is
in advanced regulatory development for ZEPIZURE®, an epileptic
rescue therapy, for which it was awarded a $60 million contract
with the U.S. Biomedical Advanced Research and Development
Authority (BARDA). ZEPIZURE® is based on the Company’s
award-winning needle-free autoinjector ZENEO®, designed to enable
patients and untrained caregivers to easily and instantly deliver
emergency medication via intramuscular injection on bare skin or
even through clothing. The Company’s other products in development
include rescue therapies for allergic shocks, adrenal
insufficiencies, opioid overdose and asthma attacks.
For further information, please contact:
Investors Natasha DrapeauCohesion Bureau+41 76 823
75 27natasha.drapeau@cohesionbureau.com |
MediaSophie BaumontCohesion Bureau+33 6 27 74 74
49sophie.baumont@cohesionbureau.com |
|
- Crossject_Press release_ODDO_28112023_EN
Crossject (EU:ALCJ)
過去 株価チャート
から 4 2024 まで 5 2024
Crossject (EU:ALCJ)
過去 株価チャート
から 5 2023 まで 5 2024